eCommons@AKU
Department of Paediatrics and Child Health

Division of Woman and Child Health

5-24-2022

Effect of bovine lactoferrin on seroconversion following polio
vaccine administration in children: Protocol for a double-blinded
randomised controlled trial
Atif Habib
Aga Khan University, atif.habib@aku.edu

Sidrah Nausheen
Aga Khan University, sidrah.nausheen@aku.edu

Shanila Nooruddin
Aga Khan University, shanila.nooruddin@aku.edu

Tooba Javed
Aga Khan University

Tariq Samejo
Aga Khan University, tariq.samejo@aku.edu

See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr
Part of the Bacteria Commons, Infectious Disease Commons, Pediatrics Commons, and the Women's
Health Commons

Recommended Citation
Habib, A., Nausheen, S., Nooruddin, S., Javed, T., Samejo, T., Hussain, A., Namdave, S., Amirali, S., Umer, M.,
Sheikh, L. (2022). Effect of bovine lactoferrin on seroconversion following polio vaccine administration in
children: Protocol for a double-blinded randomised controlled trial. BMJ Open, 12(5).
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/1158

Authors
Atif Habib, Sidrah Nausheen, Shanila Nooruddin, Tooba Javed, Tariq Samejo, Amjad Hussain, Suneeta
Namdave, Sehrish Amirali, Muhammad Umer, and Lumaan Sheikh

This article is available at eCommons@AKU: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr/1158

Protocol

Effect of bovine lactoferrin on
seroconversion following polio vaccine
administration in children: protocol for
a double-blinded randomised
controlled trial
Atif Habib,1 Sidrah Nausheen,2 Shanila Nooruddin,1 Tooba Javed,1 Tariq Samejo,1
Amjad Hussain,1 Suneeta Namdev,3 Sehrish Amirali,1 Muhammad Umer,1
Lumaan Sheikh,2 Imtiaz Hussain,1 Shabina Ariff  ,3 Sajid Soofi  1,4

To cite: Habib A, Nausheen S,
Nooruddin S, et al. Effect
of bovine lactoferrin on
seroconversion following
polio vaccine administration
in children: protocol for a
double-b linded randomised
controlled trial. BMJ Open
2022;12:e050849. doi:10.1136/
bmjopen-2021-050849
► Prepublication history and
additional supplemental material
for this paper are available
online. To view these files,
please visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2021-050849).

Received 03 March 2021
Accepted 22 April 2022

© Author(s) (or their
employer(s)) 2022. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published by
BMJ.
For numbered affiliations see
end of article.
Correspondence to
Dr Shabina Ariff;
shabina.ariff@a ku.edu

ABSTRACT
Introduction The oral polio vaccine (OPV) has substantial
results in eliminating wild poliovirus and the vaccine
of choice in polio eradication. However, the mucosal
immunity induced by the OPV is still uncertain. Literature
has shown that bovine lactoferrin (BLF) is a safe and
useful protein found in cow’s milk with extraordinary
antimicrobial, antiviral, antiinflammatory and immune-
modulatory functions that help children’s gut to fight
against micro-organisms like poliovirus. However, limited
data exist regarding the effect of BLF on polio vaccine
immune response. The primary objective is to evaluate
the effect of BLF in enhancing mucosal and humoral
immunity in children following the administration of oral
and inactivated polio vaccines.
Methods and analysis This is a two-arm double-blinded
randomised controlled trial comparing 462 neonates (231
in both groups) receiving either BLF or placebo with breast
milk. The intervention is administered from day 1 till 6
weeks of age to a full-term healthy singleton newborn
born at the Aga Khan University Hospitals, Karachi,
Pakistan. The primary outcome is the seroconversion, 1
month after the receipt of two doses of OPV (at 10 weeks).
For descriptive statistical analysis, Stata will be used, the
frequency with percentages will be reported to describe
baseline characteristics of the participants. A χ2 test will
be used to compare categorical variables and a simple t
test to compare continuous variables. The proportion of
seroconversion and shedding will be compared using χ2
test or Fisher’s exact test.
Ethics and dissemination The Ethics approval has been
granted by the Ethics Review Committee (ERC) of Aga Khan
University for the proposed trial (ID: 2019-1955-5013).
Furthermore, the National Bioethics Committee (NBC) of
Pakistan has also approved the study for human subject
research (ID: 4–87/NBC-443/19/669). Study findings
will be disseminated through presentations at scientific
conferences and educational practice workshops and will
be published in an international peer-reviewed scientific
journal.
Trial registration number NCT04432935; ClinicalTrials.
gov.

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Randomisation will produce comparable groups and

eliminate bias in treatment assignment.
⇒ As it is double blinded, the unbiased selection of the

participants will be ensured, resulting in reliable and
robust data.
⇒ Collection of blood and stool samples at various
time points will provide robust data on the effect of
Lactoferrin on polio seroconversion.
⇒ Complexity of the trial may result in loss to follow-
ups, which has been adjusted in sample size
estimation.
⇒ The primary analytic approach will be an intention to
treat analysis to avoid the effects of crossover and
dropouts.

INTRODUCTION
The global polio eradication initiative was
adopted in 1988 and since then the number
of cases due to polioviruses has decreased by
over 99.9%. In 2019, the WHO reported 143
cases of paralytic poliomyelitis due to wild
polioviruses worldwide.1 In the year 2020, the
remaining endemic areas with wild poliovirus
circulation were limited to Pakistan, Nigeria
and Afghanistan.2 3 The oral polio vaccine
(OPV) has been successful in producing
substantial results in eliminating the wild
poliovirus and has been the vaccine of choice
in polio eradication, especially in developing
countries.4 5 However, its effectiveness studies
have shown that the OPV stimulated a lower
antibody response in developing countries.6–11
Factors such as repeated illnesses, malnutrition, gut barrier dysfunction and shorter
duration of breast feeding in infancy are associated with diminished OPV response.12–15
Malnutrition in Pakistan is a persistent
concern. According to the recent National
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Nutrition Survey, 40% of under-5 children are stunted with
a high prevalence of micronutrient deficiencies.16 Infectious diseases affecting malnourished children is another
public health issue as it is related to high child mortality
in under 5 years of children.17 Studies also suggested that
malnourished children have a compromised mucosal and
intestinal barrier, which is a risk factor for lower mucosal
protection against poliovirus and a major determinant
of the humoral response against OPV.18 19 This phenomenon has been corroborated in studies conducted in Pakistan.14 20 21
Breast feeding is a dynamic and highly recommended
practice as it is unique in protecting children from infections as a first line of defence and serves as a source of
nutrition for their optimal growth and development;
being free from environmental contaminants.22 23 Its
anti-
infective, anti-
inflammatory and immune regulatory compounds include antibodies, glycan, lactoferrin,
leukocytes, cytokines, which play a key role in immunity
development.24 25 Exclusive breastfeeding for the first 6
months followed by partial continuation into the second
year of life has been staunchly encouraged by international health agencies.26 However, as per the Pakistan
Demographic Health Survey, 20% of children start breast
feeding within the first hour of birth, and 48% of children under age 6 months are exclusively breastfed.27
Lactoferrin which is believed to be an immune modulator is found in human colostrum, but its quantity starts
decreasing in mature milk.28 Evidence suggests that lactoferrin enhances a child’s immunity against gastrointestinal infections by inhibiting the growth of bacteria by
iron deprivation, further it also inhibits the activity of the
virus by preventing virus attachment to the intestinal cells
and by binding to the viral particle at the postadsorption
step. Hence, the children become less susceptible to the
virus that replicates in the gut such as rotavirus, poliovirus and adenovirus.29–32 Several studies have reported
the antiviral activity of lactoferrin against different types
of viruses that replicate in the gut such as rotaviruses,
polioviruses and adenoviruses, and in almost all cases,
the effect takes place mainly in the early phase of viral
infection by preventing the adsorption of the virus to the
target cells.33 34
Limited data exist regarding the efficacy of bovine
lactoferrin (BLF) on polio immune response. Yet,
trials investigating the enhanced efficacy of the Bacille
Calmette-
Guerin (BCG) vaccine after induction of
Lactoferrin have shown promising results.35 36 Given that
lactoferrin has extraordinary antimicrobial, antiviral,
anti-inflammatory and immune-modulatory functions, a
new window of opportunity can be created if its effects are
assessed on the level of seroconversion of polio vaccine in
children. Pertaining to the scarcity of data, the present
study will add to the existing pool of knowledge regarding
the use and effectiveness of lactoferrin on intestinal
and humoral immunity produced by the bivalent OPV
(bOPV) and trivalent inactivated polio virus vaccine given
during the routine immunisation (RI). This trial will be
2

engendered knowledge on the anti-infective properties of
lactoferrin that will contribute towards the eradication of
this debilitating disease from our country.

HYPOTHESIS
This trial will address the following primary questions:
1. Is there a difference in serum antibody levels against
poliovirus types 1 and 3 between children receiving lactoferrin versus those receiving placebo at 10 weeks of
age (1 month after second OPV dose)?
2. Is there a difference in serum antibody levels against
poliovirus types 1, 2 and 3 between the two groups at
18 weeks of age (1 month after completion of the RI
schedule)?
3. Is there a difference between children receiving lactoferrin versus those receiving placebo in excretion of
poliovirus types 1 and 3 in stools at 19 weeks of age
(1 week after administration of a challenge dose of
bOPV)?
SPECIFIC OBJECTIVES
Primary objective
1. To compare humoral immunity represented by seroconversion (presence of detectable antibodies to poliovirus types 1 and 3 in serum) 1 month after receipt
of two doses of OPV (at 10 weeks) in both the study
arms (lactoferrin vs placebo).
Secondary objectives
1. To compare humoral immunity represented by seroconversion (presence of detectable antibodies to poliovirus types 1, 2 and 3 in serum) after completion of
the RI doses/schedule (administered at 6, 10 and 14
weeks of age) at 18 weeks of age (4 weeks after the last
RI dose) in both study arms.
2. To compare intestinal immunity represented by shedding of poliovirus types 1 and 3 1 week after a challenge dose of bOPV administered at 18 weeks of age (1
month after completion of the RI doses/schedule at 14
weeks of age) in both the study arms.
3. To compare the duration of shedding among the two
study arms (lactoferrin vs placebo) represented by
shedding at 1 and 2 weeks, that is, 19 and 20 weeks of
age after the challenge dose of bOPV administered at
18 weeks.
METHODOLOGY
Study design
This is a double-blind (participants, healthcare workers
and investigators will be blinded) randomised placebo-
controlled trial that will compare intestinal and humoral
immunity following completion of the RI schedule for
poliovirus in children receiving a nutritional supplement
(lactoferrin) in the intervention arm vs those receiving
placebo in the control arm.
Habib A, et al. BMJ Open 2022;12:e050849. doi:10.1136/bmjopen-2021-050849
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Study setting
The trial will be conducted at the Aga Khan University
Hospital and its associated secondary health facility in
Kharadar, Karachi and district Dadu of Sindh province
in Pakistan. The sites are, providing services in obstetrics,
gynaecology, neonatology, paediatrics, child health and
family planning/infertility. Services for consulting clinics,
diagnostics, immunisation, operating rooms, inpatient
wards, laboratory, pharmacy and vaccination as per the
Expanded Program on Immunization (EPI) are also
offered in these centres.
Study population
The trial population will be healthy term newborn
babies born. For this purpose, pregnant women of 18–45
years, in 28–38 weeks of gestation age will be identified
and screened in antenatal clinics. Infants born to these
women will be enrolled in the trial.
Eligibility Criteria
Inclusion Criteria
Healthy singleton full-term births weighing at least 1200
g, and with an APGAR (A-Apperance, P-pulse, G-grimace,
A-activity, R-respiration) score of 7 or higher at 5 min
after delivery, tolerating oral feed, with no respiratory
distress, absence of danger signs and congenital anomaly
will be included in the trial after obtaining consent from
the mother/family.
Exclusion criteria
Preterm and newborns less than 1200 g, sick newborns
according to predefined criteria (does not tolerate oral
feeds, severe respiratory distress including respiratory
rate less than 20 bpm, grunting, central cyanosis, severe
chest in-drawing, convulsions, unconsciousness and hypothermia of less than 32°C, apnea, congenital malformation) will be excluded from the trial.
Discontinuation criteria
The discontinuation criteria will be withdrawal of consent
for participation, identification of immunodeficiency
disorder, blood disorder or other medical condition for
which continued participation would pose risk to participants, receipt of immunosuppressive medications and
premature termination of the trial.
Sample size
We calculated an overall sample size of 231 neonates in
each group (462 neonates in both groups). We estimated
the sample size assuming one-sided test with a probability
of error (alpha) of 0.05, a seroprevalence of 70% after two
doses of OPV at 10 weeks, a power of 80%, an absolute
increase of 10% in the seroconversion in the intervention
group, a loss to follow-up of 10% and a 95% level of confidence. This sample will be adequate for measuring the
outcome for all the objectives mentioned above.
Randomisation
After birth, screening of the participant will be conducted
by the trial physician. All eligibility criteria will be checked
Habib A, et al. BMJ Open 2022;12:e050849. doi:10.1136/bmjopen-2021-050849

using a checklist before randomisation. With the confirmation of the eligibility, the participant will be randomly
assigned to either control or intervention group. A
unique randomisation ID or code will be assigned to
the participant in either of these arms. Assignment of
treatment will be conducted as a 1:1 ratio per computer-
generated randomisation sequence, with random block
sizes of 4 or 6. This will be done using a dedicated study
computer. A predefined list of randomisation IDs will be
given to the study personnel and the study staff will take
the next sequentially numbered sachet from the packet.
Allocation concealment will be achieved by having identical sachets, that is, lactoferrin and placebo both will look
identical and will be in identical packaging.
Participants, field staff interacting with participants,
and lab personnel will be blinded to randomisation
assignment. To ensure appropriate concealment, both
the lactoferrin and placebo are made identical with the
same colour, consistency and quantity and using identical
packaging in identical ways. Only Data Safety and Monitoring Board (DSMB) will have the authority to unblind
in the case of adverse events (AE) or serious adverse
events (SAE).
Sampling process
Eligible participants will be enrolled at the time of birth.
Cord blood for maternal antibodies will be collected
along with the first bOPV (OPV0=zero-dose OPV) administration. The intervention arm will receive BLF and the
control arm will receive a placebo with breast milk on
daily basis from day 1 to 6 weeks of life. The total follow-up
period per participant will be 20 weeks of life. A detailed
methodology explanation is demonstrated in table 1.
For both intervention and control arms, a blood sample
will be collected during the clinic visit before administration of RI of bOPV, at 6 weeks and 10 weeks. The challenge dose of bOPV will be administered at 18 weeks of
age after 4 weeks of the last RI dose given at 14 weeks of
age, and a blood sample will also be collected. The serum
will be assessed for the presence of poliovirus types 1, 2
and 3 antibodies. Stool samples will be collected at 6, 7,
8, 14, 18, 19 and 20 weeks of age and assessed for the
presence of poliovirus types 1 and 3 through virus isolation techniques. The container for stool collection will be
provided to the parent beforehand by the field staff.
Trial team and training
The trial team will be comprised of a research manager,
research medical officers, research assistants and a phlebotomist. The manager will supervise the overall activity
of the trial, whereas the medical officers will screen,
recruit and counsel mothers on how to use lactoferrin.
The research assistants will collect data on compliance
and trial outcomes, whereas the lab assistants will be
responsible for blood and stool sample collection and
processing. The trial teams will undergo intensive 3–5
days of training in trial procedures and good clinical practice. This will be conducted by AKU faculty members who
3
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Stool
Stool
Stool
Stool
Placebo
Blood* bOPV
Placebo

Interventions
First dose of BLF
The first dose of BLF or placebo will be dispensed by a
trained trial physician in front of the mother/caregiver at
the hospital. The BLF or placebo will begin on the first day
of life of the newborn (day 1) with a single dose dissolved
in milk (preferably breast milk, otherwise formula milk);
preferably before the first dose of BCG, and OPV is given
to the baby. Daily follow-up of the newborns in both arms
will be organised during the entire course of the hospital
stay to assess vital information along with administration
of BLF and placebo daily single dose.

*Cord blood=maternal antibodies.
IPV, injectable polio vaccine ; OPV, oral polio vaccine.

Stool
Stool

20 weeks
19 weeks

Blood
Stool bOPV
Blood Stool
bOPV
bOPV +IPV
Stool
bOPV +IPV
Stool
bOPV
Blood
bOPV
Blood

18 weeks
14 weeks
10 weeks

Stool

8 weeks

Stool

Blood
Stool bOPV
Blood
Stool bOPV
Lactoferrin
Blood* bOPV

7 weeks
6 weeks
Day 1 to 6 weeks
Birth

Lactoferrin

Arm

Age of participant

Summary of trial procedures
Table 1

4

will provide essential information on standard operating
procedures and data collection instruments. The training
will be conducted at the field site, for which multimedia,
demonstrative videos and flip charts will be used with
relevance to the trial. Furthermore, lecture rooms, as well
as operational fields for real-life field scenarios, will be
used. Similarly, the teams will also be trained on effective communication for delivering information and counselling the family at the household level as per the study
requirements. Educational materials such as information,
pictorial booklet and flip charts in the local language will
be provided to trial staff. The sample collection team will
be trained as per the WHO guidelines37 by trained lab
staff.

Follow-up for compliance and to assess the well-being of
participants
At discharge, the mother of the enrolled newborn dyad
will be provided with 1 week supply of BLF or placebo
along with instructions on how and when to administer
it to the infant. Lactoferrin or placebo will be administered daily until 6 weeks of life. Newborns from both arms
will be followed weekly until 6 weeks of life for general
well-being and compliance. Compliance will be assessed
by counting the used sachets of lactoferrin or placebo as
mothers will be instructed to keep the empty sachets in a
dedicated container issued by trial staff. Mothers will also
be asked about intake of the supplement by the infant
(ie, did the infant spit it out, vomited, etc). If the infant
had vomited or spit out the lactoferrin/placebo, then the
dose would not be repeated for the day.
Routine Immunisation
The parents of the enrolled infant will be strictly advised
to administer all vaccinations according to the EPI
schedule (table 2). They will be asked to come to the trial
hospitals for vaccinations and follow-up. Compliance with
vaccination will be facilitated by reminder calls before the
date of vaccination and if the participant does not come
to the hospital for 2 days after the due date of vaccination,
the vaccine will be administered at home by trial staff.
Measures to ensure compliance and minimise loss to followup and missing data
► During recruitment: only women who have lived
at their current residence for the previous year and
Habib A, et al. BMJ Open 2022;12:e050849. doi:10.1136/bmjopen-2021-050849

BMJ Open: first published as 10.1136/bmjopen-2021-050849 on 24 May 2022. Downloaded from http://bmjopen.bmj.com/ on June 21, 2022 at Aga Khan University. Protected by copyright.

Open access

Table 2 Routine immunisation schedule in Pakistan
Age

Vaccines

At birth
6 weeks

BCG and bOPV
Penta-I, Pneumo-I, bOPV-I and Rota-I

10 weeks

Penta-II, Pneumo-II, bOPV-II and Rota-II

14 Weeks

Penta-III, Pneumo-III, bOPV-III and IPV

9 Months
15 Months

Measles-I
Measles-II

BCG, Bacille Calmette-Guerin; OPV, oral polio vaccine.

►

►

►

►

►

confirm that they will not move away from their home
for 5 months following delivery will be recruited.
Moreover, after the delivery of the child, plans for
moving will be ascertained (before randomisation of
the child). If the mother’s plans have changed, the
child will not be recruited.
After randomisation, families will be instructed to
inform the study team if they plan to move from
their residence and to provide the new address for
follow-up. Even if a family is not within the catchment
area of the health facility, they will be followed by the
study team for the administration of immunisation
and supplement/placebo.
To ensure compliance with the RI schedule, mothers
will be contacted 1 week before the child is due to
receive their vaccine dose to remind them. If the
mother does not bring the child for up to 2 days after
the vaccination due date, study staff will administer
the vaccine at home.
To facilitate the assessment of compliance with administration of the supplement/placebo, mothers will be
instructed to keep the empty sachets of supplement/
placebo in a dedicated container. Study staff will visit
the families weekly to check on the child, count the
empty and full sachets and record basic information
regarding the child’s acceptance of the supplement/
placebo.
Blood will be collected before administration of the
vaccine, the participant will be reminded ahead of the
appointment date and if they do not show up, the next
day study staff will do a home visit to collect blood or
stool specimen.
In case of withdrawal of consent/refusal to continue
the study, data will be collected on the reasons for
withdrawal to determine if it is related to the vaccine,
supplement or other reasons. This will facilitate a
sensitivity analysis to determine the possible effects of
missing data on the results of this trial.

Post vaccination procedures
For both intervention and control groups, a blood sample
will be collected in the hospital at 18 weeks of age (4 weeks
after the last RI dose given at 14 weeks of age). One day
before 18 weeks of visit, the parents will collect stool from
the participant/infant and bring it the next day to the
Habib A, et al. BMJ Open 2022;12:e050849. doi:10.1136/bmjopen-2021-050849

hospital. During the 18-week visit, after the blood draw
and collection of the stool specimen, the participant will
be given a challenge dose of OPV. Thereafter, at 19 and
20 weeks of age, stool will be collected from the participants and field workers will collect the specimens from
the participants’ homes. The serum will be assessed for
the presence of poliovirus type 1; 2 and 3 antibodies and
stools will be assessed for the presence of poliovirus types
1 and 3 through virus isolation techniques.
Sample collection and processing
For immunity assessment, 3 mL of whole blood will be
collected by a trained phlebotomist from each subject.
After collection, the blood samples will be allowed to
clot, centrifuged to separate serum and transported to
the Nutrition Research Laboratory (NRL) at the AKU,
Karachi under cold chain conditions, where they will be
stored at −20 C until shipment to the Centers for Disease
Control and Prevention (CDC), Atlanta, Georgia, USA.
Neutralising antibodies will be determined by the method
recommended by the WHO and CDC.38 39
For stool collection, containers will be provided to the
families, which will be collected by the study team for
processing. The stool samples will be transported with ice
packs to the NRL at the AKU, Karachi under cold chain
conditions. At NRL, three aliquots of stool samples will
be prepared, two of them will be transported to the Polio
Reference Laboratory at NIH Pakistan under strict cold
chain maintenance, whereas one aliquot will be achieved
at NRL as a backup. Stool specimens will be examined for
the presence of poliovirus as per the standard procedures
and guidelines.38 39
Data collection
Source document file for each participant will have a trial-
assigned separator or tag, which will help the hospital
staff in identifying the enrolled participants. Data will be
collected from the participants of the trial at the hospital
and will be managed at the time of screening, enrollment and follow-
up visits and during identifying AE/
SAE. This data will be collected on hard copies and in
electronic format using tablets wherever possible and will
be entered in a predesigned screen made by the Data
Management Unit, AKU trial staff daily. Screening/eligibility forms will be used for the participants who meet the
eligibility criteria. Participants who will be determined
to be eligible after screening will be enrolled after the
informed consent by the parents (online supplemental
file 1). Enrolment form mainly comprises the basic information, which will include study ID, randomisation ID,
supplement or placebo details in both the cases whether
given or reason, if it is not given. Assigned trial staff will
conduct the weekly follow-up visits within the hospital,
home visits, inpatient (readmission in the study site
hospital or any other hospital) or via phone calls. These
weekly follow-ups are designed to get maximum information from the parents about the enrolled study participant,
which mainly includes questions about feeding practices,
5

BMJ Open: first published as 10.1136/bmjopen-2021-050849 on 24 May 2022. Downloaded from http://bmjopen.bmj.com/ on June 21, 2022 at Aga Khan University. Protected by copyright.

Open access

history in case of in-patient admission or illness, supplement administration and history of supplement consumption and outcomes of the visits. Furthermore, AE/SAE
will be examined and assessed separately through AE/
SAE form and will be initially examined by the trial physician and will be reported to the DSMB and the trial investigators. For participants who are non-compliant or lost
to follow-up, data on the reason for dropping out will be
collected including whether they did not complete lactoferrin/placebo doses or immunisation per RI schedule
(number of doses and timing of vaccination).
Process of informed consent
The consent form (online supplemental file 1) briefly
states the project objectives, procedures, process of confidentiality and gives participants the right to withdraw at
any time. Trained research staff preferably nurses will
introduce the trial to potential participants. All women
will receive information about the trial in their language
of choice either English or Urdu. The language used will
be non-technical and easily understood. Participants will
be given time to reflect on the information and given an
opportunity to ask questions. If willing to participate, the
informed consent form (online supplemental file 1) will
be signed by the participant and research assistant.
If the mother is illiterate, Independent Literate Witness
will sign the consent (online supplemental file 1) and
the mother will affix a thumb impression on the consent
form (online supplemental file 1). Participants will be
free to withdraw from the trial at any stage without loss
of benefits. The telephone numbers of investigators will
be made available to participants in the event that they
require further information or assistance.
Data management and analysis
The primary outcomes will be measured for both the
arms, that is, control and intervention. Two approaches
will be followed to assess the impact of the intervention
on the outcome. Following the descriptive statistical analysis for assessment within and between the control and
intervention arms, while adjusting for the confounding
variables, and then will do the same at the end of the trial.
Stata will be used for descriptive statistical analysis, the
frequency with percentages will be reported to describe
baseline characteristics of the trial population.
A χ2 test will be used to compare categorical variables
and a simple t test will be used to compare continuous
variables. Seropositivity is defined as reciprocal titers of
poliovirus neutralising antibodies ≥8; seroconversion is
defined as the change from seronegative to seropositive
(from reciprocal titre of <8 to ≥8) or participants who
demonstrate a titre fourfold higher than the expected
fall in maternally derived antibodies, assuming a half-
life of 28 days. Shedding of poliovirus is defined as isolation of poliovirus in a stool sample. The primary analytic
approach will be the intention to treat analysis. For participants who are non-compliant or lost to follow-up data on
the reason for dropping out will be collected including
6

whether they did not complete lactoferrin/placebo doses
or immunisation per RI schedule (number of doses and
timing of vaccination). The proportion of seroconversion
and shedding in the trial arms will be compared using the
χ2 test or Fisher’s exact test.
DATA AND SAFETY MONITORING BOARD
A DSMB has been constituted to review the data of
AE/SAE cases to monitor the progress of the trial and
assess the safety of the intervention and the participants.
The members include an infectious disease specialist,
a paediatrics gastroenterologist, a neonatologist and a
biostatistician. The DSMB will examine all the AE/SAE
cases, rate of enrollment and compliance to the intervention throughout the study. An interim analysis will be
conducted when approximately 50% of the infants are
enrolled. This analysis will be conducted in a blinded
manner (intervention groups X and Y). The randomisation code will only be unblinded by following the recommendation of the DSMB if there is any clear evidence of
an AE/SAE or mortality between the two groups. The
DSMB will advise the trial investigators on continuation,
modification or termination based on pre-
established
stopping rules.
ETHICAL CONSIDERATION AND CONFIDENTIALITY
All personally identifiable information of the trial participants will be kept confidential. It may only be accessed
by the DSMB. Written informed consent (online
supplemental file 1) will be obtained from all participants’ parents before the recruitment in the trial, data
collection and specimen collection. The Ethics Review
Committee (ERC) of Aga Khan University has approved
the proposed trial (ID: 2019-1955-5013). Furthermore,
the National Bioethics Committee (NBC) of Pakistan
has also approved the study for human subject research
443/19/669). The study contains all
(ID: 4–87/NBC-
items required by the WHO Trial Registration Data Set.
The study does not plan to share individual deidentified
participant data, including data dictionaries. The results
will be shared as conference presentations and publications in peer-reviewed journals. However, the data sets
used for the article and the study will be available from
the corresponding author on request.
DISCUSSION
The potential use of the findings of this study at the
community level in Pakistan will serve as a new hope for
the eradication of polio from the country. The ultimate
goal of polio vaccination is to protect against the disease,
encompassing the ability to limit transmission between
infected individuals and those non-infected that are at
risk from contact. Supporting evidence from this study
will provide a unique opportunity to assess the effects
of lactoferrin on the level of seroconversion following
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poliovirus vaccination in children as an effective adjuvant to enhance efficacy of the polio vaccines. Being
one of the last reservoirs of poliomyelitis, Pakistan needs
innovative and safe approaches like lactoferrin that can
interfere with the endemic occurrence of polio, along
with addressing various factors like malnutrition, breast
feeding, administration of RI, etc, which decrease the
immunity levels among the children, making them more
prone to the infection.

PATIENT AND PUBLIC INVOLVEMENT
The public was not involved in the design of the research
tools, but they will be a part of the trial and their feedback
will be sought regarding intervention acceptability. The
key findings will be shared with their representatives as
part of the dissemination plan at the local level.
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